SUPERNUS PHARMACEUTICALS, INC.
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
SUPN$28.75+4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| (unaudited) | ||
| Cash flows from operating activities | ||
| Net loss | $(2,293) | $(11,827) |
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||
| Depreciation and amortization | 26,132 | 20,383 |
| Amortization of premium/discount on marketable securities | (192) | (1,074) |
| Change in fair value of contingent consideration | 2,391 | 7,660 |
| Realized loss (gain) from sale of marketable securities | (21) | 9 |
| Share-based compensation expense | 8,480 | 8,068 |
| Deferred income tax expense (benefit) | 5,916 | (3,990) |
| Noncash lease expense | 2,258 | 1,341 |
| Inventory valuation write-down | 1,815 | 547 |
| Payment of contingent consideration | — | (4,900) |
| Other noncash adjustments, net | 284 | 476 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 5,619 | (3,563) |
| Inventories | (105) | 4,731 |
| Prepaid expenses and other assets | (12,432) | 7,372 |
| Accrued product returns and rebates | 28,623 | 1,428 |
| Accounts payable and other liabilities | 49 | 3,938 |
| Net cash provided by operating activities | 66,524 | 30,599 |
| Cash flows from investing activities | ||
| Purchases of marketable securities | (78,438) | (118,557) |
| Maturities of marketable securities | 59,220 | 156,201 |
| Purchases of property and equipment | — | (327) |
| Net cash provided by (used in) investing activities | (19,218) | 37,317 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock | 13,670 | 2,042 |
| Employee taxes paid related to net share settlement of equity awards | (4,555) | (3,341) |
| Payment of contingent consideration | — | (20,100) |
| Net cash provided by (used in) financing activities | 9,115 | (21,399) |
| Net change in cash, cash equivalents, and restricted cash | 56,421 | 46,517 |
| Cash and cash equivalents at beginning of year | 129,898 | 69,331 |
| Cash, cash equivalents, and restricted cash at end of year | $186,319 | $115,848 |
| Reconciliation of cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets | ||
| Cash and cash equivalents | $184,869 | $115,848 |
| Restricted cash | 1,450 | — |
| Total cash, cash equivalents, and restricted cash shown in the statement of cash flows | $186,319 | $115,848 |
| Supplemental cash flow information | ||
| Cash paid (refund received) for income taxes | $(412) | $274 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.